The changing landscape of systemic therapy in the treatment of synchronous metastatic hormone-sensitive prostate cancer

医学 醋酸阿比特龙酯 多西紫杉醇 前列腺癌 内科学 癌症 全身疗法 肿瘤科 雄激素剥夺疗法 乳腺癌
作者
Edward Lambert,Nicolaas Lumen,Valerie Fonteyne,Daan De Maeseneer,Sofie Verbeke,Geert Villeirs,Kathia De Man,Charles Van Praet
出处
期刊:Clinical Genitourinary Cancer [Elsevier BV]
标识
DOI:10.1016/j.clgc.2022.11.001
摘要

To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a "real-world" setting and to explore reasons why contemporary standard of care (SOC) was not administrated to the patient.Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction of apalutamide (Time period 4, March 2018-October 2021). For every time period, we evaluated the initiated additional ST. In case patients received treatment that differed from contemporary SOC according to guidelines, reasons for this difference were explored.In total, 243 patients were included. A progressive decline in ADT monotherapy from 85% to 29% over time was observed. The proportion of patients receiving additional STs increased from 34% to 59%. Forty percent of patients were not treated according to contemporary SOC, but this percentage varied strongly per time period (10%, 67%, 53%, and 32% from time period 1 to time period 4 respectively). Reasons for these variations were heterogenous and varied across the 4 time periods. Patients being unfit for treatment and treating physicians failing to consider additional STs were the most prevalent reasons. The proportion of patients unfit for additional ST decreased from 18% to 4% over time.Use of ADT monotherapy declined gradually after the introduction of additional systemic treatments. The proportion of patients unfit for additional ST declined as more treatments became available. Although compliance to SOC increased over time, these real-world data show that adherence to clinical practice guidelines remains suboptimal. Efforts should be made by clinicians to increase the adherence to practice guidelines.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
专注的铃兰完成签到,获得积分20
刚刚
刚刚
霜石完成签到,获得积分10
刚刚
1234完成签到,获得积分20
1秒前
凉凉发布了新的文献求助10
1秒前
纯真的幼丝完成签到,获得积分10
1秒前
2秒前
小马甲应助驴脾气采纳,获得10
2秒前
2秒前
grey完成签到,获得积分20
2秒前
简之发布了新的文献求助10
3秒前
4秒前
5秒前
春日午后发布了新的文献求助10
6秒前
英姑应助诚心的醉卉采纳,获得10
6秒前
所所应助Calvin采纳,获得10
6秒前
乐乐应助dan采纳,获得10
6秒前
梨凉完成签到,获得积分10
6秒前
情怀应助ljj采纳,获得10
6秒前
6秒前
CHJ发布了新的文献求助10
7秒前
随风沙ZYX完成签到 ,获得积分10
7秒前
7秒前
HenryXiao完成签到,获得积分10
8秒前
Jeffery完成签到,获得积分10
8秒前
grey发布了新的文献求助10
9秒前
pp发布了新的文献求助10
9秒前
花花哈完成签到,获得积分10
10秒前
10秒前
玉灵子发布了新的文献求助10
10秒前
10秒前
Jeffery发布了新的文献求助10
11秒前
脑洞疼应助大凯采纳,获得10
11秒前
ding应助hehe采纳,获得10
11秒前
11秒前
海鸥别叫了完成签到 ,获得积分10
11秒前
zhao应助熊大采纳,获得10
12秒前
12秒前
SciGPT应助miemie采纳,获得10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6429780
求助须知:如何正确求助?哪些是违规求助? 8245967
关于积分的说明 17535250
捐赠科研通 5485660
什么是DOI,文献DOI怎么找? 2895650
邀请新用户注册赠送积分活动 1872101
关于科研通互助平台的介绍 1711492